Ipragliflozin/ja: Difference between revisions
Ipragliflozin/ja
Created page with "{{Pathnav|Medication/ja|Diabetes medication/ja|SGLT2 inhibitor/ja|frame=1}} {{Infobox drug | drug_name = | IUPAC_name = (1''S'')-1,5-Anhydro-1-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-<small>D</small>-glucitol <!-- Chemspider ---> | image = Ipragliflozin structure.svg | width = 275 | image2 = Haworth projection of ipragliflozin.svg | width2 = 225 | caption = Haworth projection/ja (bottom)" Tags: Mobile edit Mobile web edit |
Created page with "<!-- Clinical data --> | tradename = Suglat | Drugs.com = | MedlinePlus = | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | pregnancy_AU_comment = | pregnancy_US = <!-- A / B / C / D / X / N --> | pregnancy_category = | legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> | legal_AU_comment = | legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> | legal_NZ = <!--Class A, B, C --> | legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM..." Tags: Mobile edit Mobile web edit |
||
| Line 10: | Line 10: | ||
| caption = [[Haworth projection/ja]] (bottom) | | caption = [[Haworth projection/ja]] (bottom) | ||
<!-- Clinical data --> | <!-- Clinical data --> | ||
| tradename = Suglat | | tradename = Suglat | ||
| Line 26: | Line 25: | ||
| legal_US_comment = Not available | | legal_US_comment = Not available | ||
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV--> | | legal_UN = <!-- N I, II, III, IV / P I, II, III, IV--> | ||
| legal_status = Rx-only <small>([[Japan|JP]])</small> | | legal_status = Rx-only <small>([[:en:Japan|JP]])</small> | ||
| routes_of_administration = [[Oral administration| | | routes_of_administration = [[Oral administration/ja|口から]] ([[Tablet (pharmacy)/ja|タブレット]]) | ||
<!-- Pharmacokinetic data --> | <!-- Pharmacokinetic data --> | ||
| bioavailability = 90.2% | | bioavailability = 90.2% | ||
| protein_bound = 94.6–96.5% | | protein_bound = 94.6–96.5% | ||
| metabolism = [[UGT2B7]] (major), [[UGT2B4]], [[UGT1A8|1A8]], [[UGT1A9|1A9]] (minor) | | metabolism = [[UGT2B7/ja]] (major), [[UGT2B4/ja]], [[UGT1A8/ja|1A8]], [[UGT1A9/ja|1A9]] (minor) | ||
| metabolites = | | metabolites = | ||
| onset = | | onset = | ||
| elimination_half-life = 14.97±4.58 hours | | elimination_half-life = 14.97±4.58 hours | ||
| duration_of_action = | | duration_of_action = | ||
| excretion = [[Urine]] (67.9%), [[feces]] (32.7%) | | excretion = [[Urine/ja]] (67.9%), [[feces/ja]] (32.7%) | ||
<!-- Identifiers --> | <!-- Identifiers --> | ||
| CAS_number = 761423-87-4 | | CAS_number = 761423-87-4 | ||
| Line 55: | Line 50: | ||
| ChEMBL = 2018096 | | ChEMBL = 2018096 | ||
| synonyms = (1''S'')-1,5-anhydro-1-''C''-{3-[(1-benzothiophen-2-yl)methyl]-4-fluorophenyl}-<small>D</small>-glucitol | | synonyms = (1''S'')-1,5-anhydro-1-''C''-{3-[(1-benzothiophen-2-yl)methyl]-4-fluorophenyl}-<small>D</small>-glucitol | ||
<div lang="en" dir="ltr" class="mw-content-ltr"> | <div lang="en" dir="ltr" class="mw-content-ltr"> | ||